Back to Search
Start Over
Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
- Source :
- Liver Cancer, Liver Cancer, Pp 1-11 (2021)
- Publication Year :
- 2021
- Publisher :
- S. Karger AG, 2021.
-
Abstract
- Background and Aims: It remains unclear whether obesity increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C who achieved a sustained virological response (SVR) with antiviral therapy. Methods: In this multicenter cohort study, we enrolled patients with chronic hepatitis C who achieved SVR with interferon (IFN)-based therapy (IFN group) or direct-acting antiviral (DAA) therapy (DAA group) between January 1, 1990, and December 31, 2018. The patients underwent regular surveillance for HCC. Cumulative incidence of and the risk factors for HCC development after SVR were assessed using the Kaplan-Meier method and Cox proportional hazard regression analysis, respectively. Results: Among 2,055 patients (840 in the IFN group and 1,215 in the DAA group), 75 developed HCC (41 in the IFN group and 34 in the DAA group) during the mean observation period of 4.1 years. The incidence rates of HCC at 1, 2, and 3 years were 1.2, 1.9, and 3.0%, respectively. Multivariate analysis revealed that in addition to older age, lower albumin level, lower platelet count, higher alpha-fetoprotein level, and absence of dyslipidemia, obesity (body mass index ≥25 kg/m2) and heavy alcohol consumption (≥60 g/day) were independent risk factors for HCC development, with adjusted hazard ratio (HR) of 2.53 (95% confidence interval [CI]: 1.51–4.25) and 2.56 (95% CI: 1.14–5.75), respectively. The adjusted HR was not significant between the 2 groups (DAA vs. IFN; HR 1.19, 95% CI: 0.61–2.33). Conclusions: Obesity and heavy alcohol consumption increased the risk of HCC development after SVR.
- Subjects :
- obesity
Original Paper
medicine.medical_specialty
Hepatology
business.industry
Hazard ratio
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
hepatocellular carcinoma
Hepatitis C
medicine.disease
Gastroenterology
digestive system diseases
Confidence interval
Oncology
Internal medicine
Hepatocellular carcinoma
Medicine
Cumulative incidence
hepatitis c
business
Body mass index
direct-acting antivirals
RC254-282
Dyslipidemia
Cohort study
Subjects
Details
- ISSN :
- 16645553 and 22351795
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Liver Cancer
- Accession number :
- edsair.doi.dedup.....2f81b8b3e3face8ef91585eb812c5046